Effect of Adefovir dipivoxil and lamivudine in treatment of decompensated liver cirrhosis patients with YM- DD mutation

Objective To evaluate the efficacy and safety of adefovir dipivoxil and lamivudine in treatment of decompensated liver cirrhosis with YMDD mutatim.Methods 70 patients of decompensated liver cirrhois with YM-DD motif mutation were divided into adefovir dipivoxil combined lamivudine(treatment group)35 cases and lamivudi-ne alone(control group)35 eases;The patients in both groups received routine therapy and continued to receive lami-vudine at a dose of 100mg daily,moreover,the patients in treatment group received adefovir dipivoxil at a dose of 10 mg daliy.The index of ALT,Tbil,ALB,Child-Pugh score,biochemical response rate,HBV-DNA response,and adverse drug reactions were observed in two groups.Results The index of liver function and Child-Pugh scores in treatment group after treatment were better than the control group(P all<0.05);The rates of biochemical response,HBV-DNA response,HBV-DNA negative conversion in treatment group after treatment were significantly higher than the control group(P all<0.05).Conclusion Adefovir dipivoxil and lamivudine has satisfied efficacy and safety in treatment of decompensated liver cirrhosis patients with YMDD motif mutation. Key words: Lamivudine; Adefovir dipivoxil; Liver cirrhosis; YMDD mutation